Efficacy comparison of 6-month romosozumab plus denosumab versus 12-month romosozumab in Koreans
Sequential Romo6M + Dmab treatment demonstrates comparable efficacy to Romo12M treatment in improving BMD, with fewer injections and potential cost benefits.
Authors
- Seong Hee Ahn (ORCID: https://orcid.org/0000-0003-2558-2118)
- Seung‐Eun Lee
- Seongbin Hong (ORCID: https://orcid.org/0000-0002-8189-395X)
- Ha Young Kim (ORCID: https://orcid.org/0000-0002-0651-2213)
- Seung Hun Lee (ORCID: https://orcid.org/0000-0003-0496-247X)
- Beom-Jun Kim (ORCID: https://orcid.org/0000-0002-6977-9927)
- Jung-Min Koh
Institutions
- Ulsan College (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
- Ulsan University Hospital (KR)
- Gangneung Asan Hospital (KR)
- Inha University Hospital (KR)
Publication Details
- Journal
- European Journal of Endocrinology
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1093/ejendo/lvaf211
- Primary Topic
- Bone Metabolism and Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00